700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies

BACKGROUND: The risk of serious infections and poor treatment outcomes is reported to be higher in patients with diabetes compared with the general population. Omadacycline (OMC) is an intravenous (IV) and oral aminomethylcycline antibiotic approved in the US to treat acute bacterial skin and skin s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai, Manjunath P, Wilcox, Mark H, Curran, Marla, Chitra, Surya, Garrity-Ryan, Lynne, McGovern, Paul C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811084/
http://dx.doi.org/10.1093/ofid/ofz360.768
_version_ 1783462393522683904
author Pai, Manjunath P
Wilcox, Mark H
Curran, Marla
Chitra, Surya
Garrity-Ryan, Lynne
McGovern, Paul C
author_facet Pai, Manjunath P
Wilcox, Mark H
Curran, Marla
Chitra, Surya
Garrity-Ryan, Lynne
McGovern, Paul C
author_sort Pai, Manjunath P
collection PubMed
description BACKGROUND: The risk of serious infections and poor treatment outcomes is reported to be higher in patients with diabetes compared with the general population. Omadacycline (OMC) is an intravenous (IV) and oral aminomethylcycline antibiotic approved in the US to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adults. Here we assessed safety and efficacy results from OMC Phase 3 studies (ABSSSI: Omadacycline in Acute Skin and skin structure Infections Study [OASIS]-1 and OASIS-2; CABP: Omadacycline for Pneumonia Treatment In the Community study [OPTIC]), by diabetes history. METHODS: In OASIS-1 (IV to optional oral medication) and OASIS-2 (oral only), patients were randomized to OMC or linezolid (LZD) for 7–14 days. In OPTIC, patients were randomized to IV OMC or moxifloxacin (MOX) for 7–14 days, with optional transition to oral medication. Data from OASIS-1 and OASIS-2 were pooled, and patient subgroups were defined by any medical history of diabetes (type 1, type 2, or unspecified), or no medical history of diabetes. Efficacy outcomes were early clinical response (ECR) and investigator’s assessment of clinical response at post-treatment evaluation (PTE), as defined for each indication. Safety was assessed by treatment-emergent adverse events (TEAEs) and laboratory measures, and data were pooled across the three studies. RESULTS: A total of 2,150 patients were included, of whom 238 (11.1%) had any history of diabetes (n = 105 for ABSSSI, n = 133 for CABP). In the pooled ABSSSI studies and the CABP study, clinical success at ECR and PTE was similar between patients with or without diabetes, and between OMC and the respective comparator (figure). TEAEs and serious TEAEs, respectively, were reported in similar numbers of OMC-, LZD-, and MOX-treated patients with diabetes (41.8–49.3%, 4.5–7.0%) and without (41.2–48.3%, 1.6–6.9%). Rates of nausea and vomiting, respectively, in patients with diabetes were similar across treatment arms: OMC (5.0%, 5.0%), LZD (7.5%, 6.0%), MOX (7.0%, 2.8%). CONCLUSION: Omadacycline efficacy and safety were similar and consistent in patients with or without diabetes. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811084
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68110842019-10-28 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies Pai, Manjunath P Wilcox, Mark H Curran, Marla Chitra, Surya Garrity-Ryan, Lynne McGovern, Paul C Open Forum Infect Dis Abstracts BACKGROUND: The risk of serious infections and poor treatment outcomes is reported to be higher in patients with diabetes compared with the general population. Omadacycline (OMC) is an intravenous (IV) and oral aminomethylcycline antibiotic approved in the US to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adults. Here we assessed safety and efficacy results from OMC Phase 3 studies (ABSSSI: Omadacycline in Acute Skin and skin structure Infections Study [OASIS]-1 and OASIS-2; CABP: Omadacycline for Pneumonia Treatment In the Community study [OPTIC]), by diabetes history. METHODS: In OASIS-1 (IV to optional oral medication) and OASIS-2 (oral only), patients were randomized to OMC or linezolid (LZD) for 7–14 days. In OPTIC, patients were randomized to IV OMC or moxifloxacin (MOX) for 7–14 days, with optional transition to oral medication. Data from OASIS-1 and OASIS-2 were pooled, and patient subgroups were defined by any medical history of diabetes (type 1, type 2, or unspecified), or no medical history of diabetes. Efficacy outcomes were early clinical response (ECR) and investigator’s assessment of clinical response at post-treatment evaluation (PTE), as defined for each indication. Safety was assessed by treatment-emergent adverse events (TEAEs) and laboratory measures, and data were pooled across the three studies. RESULTS: A total of 2,150 patients were included, of whom 238 (11.1%) had any history of diabetes (n = 105 for ABSSSI, n = 133 for CABP). In the pooled ABSSSI studies and the CABP study, clinical success at ECR and PTE was similar between patients with or without diabetes, and between OMC and the respective comparator (figure). TEAEs and serious TEAEs, respectively, were reported in similar numbers of OMC-, LZD-, and MOX-treated patients with diabetes (41.8–49.3%, 4.5–7.0%) and without (41.2–48.3%, 1.6–6.9%). Rates of nausea and vomiting, respectively, in patients with diabetes were similar across treatment arms: OMC (5.0%, 5.0%), LZD (7.5%, 6.0%), MOX (7.0%, 2.8%). CONCLUSION: Omadacycline efficacy and safety were similar and consistent in patients with or without diabetes. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811084/ http://dx.doi.org/10.1093/ofid/ofz360.768 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Pai, Manjunath P
Wilcox, Mark H
Curran, Marla
Chitra, Surya
Garrity-Ryan, Lynne
McGovern, Paul C
700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title_full 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title_fullStr 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title_full_unstemmed 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title_short 700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
title_sort 700. safety and efficacy of omadacycline in patients with diabetes in phase 3 clinical studies
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811084/
http://dx.doi.org/10.1093/ofid/ofz360.768
work_keys_str_mv AT paimanjunathp 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies
AT wilcoxmarkh 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies
AT curranmarla 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies
AT chitrasurya 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies
AT garrityryanlynne 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies
AT mcgovernpaulc 700safetyandefficacyofomadacyclineinpatientswithdiabetesinphase3clinicalstudies